Characterizing body composition modifying effects of a glucagon‐like peptide 1 receptor‐based agonist: A meta‐analysisRuoyang Jiao, Linong Ji, Fang Lv et al.|Diabetes Obesity and Metabolism|2024Cited by 48
One or two? Comparison of the cardiorenal effects between combination therapy and monotherapy with <scp>SGLT2i</scp> or <scp>GLP1RA</scp>Mengqing Zhang, Linong Ji, Fang Lv et al.|Diabetes Obesity and Metabolism|2024Cited by 12
Population attributable fractions of modifiable risk factors for microvascular complications of type 2 diabetes in China: An analysis using national cross‐sectional dataChu Lin, Linong Ji, Fang Lv et al.|Diabetes Obesity and Metabolism|2023Cited by 5
Regional, age-specific and sex-specific trends in the prevalence of overweight or obesity in type 1 diabetes from 1980 to 2020: a meta-analysis of 78 observational studies with 650,265 participantsLinong Ji, Fang Lv, Xiaoling Cai et al.|Diabetes Research and Clinical Practice|2025Cited by 3
The association between the eGFR slope and cardiorenal prognosis in patients with renoprotective treatments: A systematic review and meta‐analysisShuzhen Bai, Linong Ji, Fang Lv et al.|Journal of Evidence-Based Medicine|2024Cited by 1